WESPAC Advisors SoCal’s Acadia Pharmaceuticals ACAD Stock Holding History

WESPAC Advisors SoCal’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-200	Closed	-$5K	–	87
2019 Q1	$5K	Hold	200	–	–	﹤0.01%	280
2018 Q4	$3K	Hold	200	–	–	﹤0.01%	299
2018 Q3	$4K	Buy	+200	New	+$3.15K	﹤0.01%	269
2018 Q2	–	Sell	-200	Closed	-$4K	–	92
2018 Q1	$4K	Hold	200	–	–	﹤0.01%	228
2017 Q4	$6K	Sell	200 -1,000	-83%	-$32K	﹤0.01%	203
2017 Q3	$45K	Hold	1,200	–	–	0.03%	129
2017 Q2	$33K	Hold	1,200	–	–	0.02%	130
2017 Q1	$41.3K	Buy	+1,200	New	+$42.4K	0.03%	123

Other funds holding ACAD

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Fidelity Investments

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

First Trust Advisors

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

D.E. Shaw & Co New York $127B AUM 43.98% 1-Year Est. Return